Hepion Pharmaceuticals
HEPA
HEPA was delisted on the 12th of May, 2025.
38 hedge funds and large institutions have $14.7M invested in Hepion Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 18 funds opening new positions, 15 increasing their positions, 2 reducing their positions, and 9 closing their positions.
650% more repeat investments, than reductions
Existing positions increased: 15 | Existing positions reduced: 2
100% more first-time investments, than exits
New positions opened: 18 | Existing positions closed: 9
31% more funds holding
Funds holding: 29 → 38 (+9)
23% more capital invested
Capital invested by funds: $12M → $14.7M (+$2.69M)
3% less call options, than puts
Call options by funds: $1.51M | Put options by funds: $1.56M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$3.51M |
| 2 |
BlackRock
New York
|
+$1.14M |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$846K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$688K |
| 5 |
SM
Sabby Management
Miami Beach,
Florida
|
+$671K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
AIGH Capital Management
Baltimore,
Maryland
|
-$2.02M |
| 2 |
WVP
Worth Venture Partners
Fort Lee,
New Jersey
|
-$512K |
| 3 |
Renaissance Technologies
New York
|
-$375K |
| 4 |
PCM
Perkins Capital Management
Wayzata,
Minnesota
|
-$329K |
| 5 |
Squarepoint
New York
|
-$245K |
HEPA Hedge Fund Activity: Q1 2021 in Review
38 of the 5,711 institutional investors tracked by Wall St. Rank reported a position in Hepion Pharmaceuticals (HEPA) for Q1 2021, worth a combined $14.7M — up 23% from $12M a quarter earlier.
Buyers outnumbered sellers: 18 funds opened new HEPA positions and 9 closed out — a net gain of 9 holders — while 15 added to existing stakes and 2 trimmed.
The largest buyer was Vanguard Group, adding an estimated $3.51M. The largest seller was AIGH Capital Management, exiting entirely with an estimated $2.02M sold.
- 38 institutional investors held Hepion Pharmaceuticals (HEPA) as of Q1 2021, up from 29 in Q4 2020.
- Funds reported $14.7M of Hepion Pharmaceuticals stock for Q1 2021, up 23% quarter-over-quarter.
- 18 funds opened new Hepion Pharmaceuticals positions in Q1 2021 and 9 closed out, a net change of +9 holders.
- The largest Hepion Pharmaceuticals buyer in Q1 2021 was Vanguard Group, an estimated $3.51M added.
- The largest Hepion Pharmaceuticals seller in Q1 2021 was AIGH Capital Management, an estimated $2.02M sold.
Based on aggregated 13F filings for Q1 2021.